House OKs PDUFA bill, sans DTC restrictions

Share this article:
The House has approved legislation that would reauthorize PDUFA and strengthen the FDA’s hand, allowing it to require post-market drug safety studies and fine companies as much as $250,000 for airing false and misleading ads.
The vote was 403-16.
Measures imposing a moratorium on advertising of new drugs and requiring preapproval of ads were stripped from the bill in committee last month.
The legislation must now be consolidated with its Senate counterpart. Barring any hitches (a contentious Senate bill on generic biologics could, if thrown into the mix, present a stumbling block) the bill could reach the President’s desk in the next two weeks.
“Now the devil’s in the details,” said John Kamp, executive director of the Coalition for Healthcare Communications. “The [Risk Evaluation and Mitigation Strategies] program giving the FDA more power to ensure drug safety is a victory for everyone. How the FDA exercises that power is going to make all the difference.”

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...